Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ranbaxy Malaysia, a wholly owned subsidiary of Ranbaxy Laboratories, has received government approval to set up a Greenfield manufacturing facility in Malaysia as an Entry Point Project (EPP).
Subscribe to our email newsletter
The RM125m ($40m) project, which will be Ranbaxy’s second manufacturing facility in Malaysia, would manufacture dosage forms including tablets and capsules primarily in the cardiovascular, anti diabetic, anti-infective and gastrointestinal segments.
Ranbaxy CEO and managing director Arun Sawhney said, "In addition to serving the local market the facility will also export products to markets like ASEAN, Middle East, Europe, Sri Lanka, China and other select countries."
Once the new facility becomes operational, it is expected to increase Ranbaxy’s total output from 1 billion doses/annum to 3 billion doses/annum in Malaysia.
Ranbaxy Malaysia managing director Jeyabalan Thangarajah said, "We are pleased that the Government of Malaysia has approved Ranbaxy’s investment in a new manufacturing facility and the project has been accorded Entry Point Project (EPP) status under the Government Economic Transformational Programme (ETP)."